Skip to main content
OpenTrials
Active, Not Recruiting

NCT Number: NCT05868044

REsponse to Combined SONS and ONS in Chronic Cluster headachE

The purpose of this study is to demonstrate the safe use of the PRIMUS System in subjects with chronic cluster headache. This is a single-centre, open label, prospective, first in human study to collect initial clinical data on the PRIMUS system for the treatment of chronic cluster headache.

Active, Not Recruiting

This study is active but is not currently recruiting participants.

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Resolve Pain

Buderim, Queensland, 4556, Australia

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Main Inclusion Criteria:

  • Able and willing to provide informed consent
  • Documented chronic cluster headache for at least 1 year as per ICHD-3 criteria
  • Attack frequency of ≥ 4 attacks per week for ≥ 4 weeks before enrolment
  • Documented failure of verapamil (failure meaning ineffective, provoked unacceptable side-effects or contra-indicated)
  • Stable on preventive treatment for at least two weeks prior to enrolment.
  • Agree to refrain from starting new prophylactic cluster headache medication or other preventive treatments, from 4 weeks before entering the baseline period throughout the duration of the study
  • MRI available (not older than 4 years prior to study enrolment) or willing to undergo an MRI to exclude structural lesions potentially causing headache
  • Able and willing to complete a headache Diary

Main Exclusion Criteria:

  • Any other chronic primary or secondary headache disorder, unless they can clearly differentiate them from cluster headache attacks based on the quality and associated symptoms
  • Concomitant neuromodulation, except tVNS
  • Previous failure to any implantable neuromodulation device for neurovascular headache
  • Have an existing Active Implantable Medical Device nearby the implant location (e.g. DBS, cochlear implant, …)
  • Metal implants in the skull (e.g. skull plates, seeds) nearby the implant
  • Have a pacemaker or implantable cardioverter defibrillator (ICD)
  • Suboccipital infiltrations with steroids and/or local anaesthetics or use of oral steroids in the past 3 months
  • Use of botulinum toxin injections in the past 12 weeks
  • Calcitonin gene-related peptide inhibitors started less than 12 weeks prior to enrolment
  • Women of childbearing age who are pregnant, nursing or not using contraception

Treatment and study plan

PRIMUS

Device

PRIMUS system

Primary outcomes

  1. Safety Evaluation

    Time frame: 4 weeks

    The primary safety assessment is the incidence of serious procedure and/or device-related adverse events in all subjects at 30 days.

  2. Safety Evaluation

    Time frame: 12 months

    The primary safety assessment is the incidence of serious procedure and/or device-related adverse events in all subjects at the end of the study.

Sponsors and collaborators

Lead sponsor

Salvia BioElectronics

Industry

Registry information

Official study title

REsponse to Combined SuPra-orbital and Occipital Nerve Stimulation in Chronic Cluster headachE With the PRIMUS System, a First in Human Study

Acronym: RESPONSE

Important dates

Study start
2023
Primary completion
2024
Study completion
2026
First posted
May 22, 2023
Registry last updated
Apr 23, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.